A crucial role of angiotensin converting enzyme 2 (ACE2) in SARS coronavirus-induced lung injury.
Level 5 - mechanism / opinion, no new human data
Animal model and preclinical mechanistic study
PubMed 16007097 · doi:10.1038/nm1267
What was done
Experimental in vivo mouse study evaluating the role of ACE2 as a SARS-CoV receptor during acute lung injury. Investigators tested the effects of SARS-CoV infection and SARS-CoV Spike protein on ACE2 expression levels and assessed whether administering the Spike protein exacerbated lung failure and whether blocking the renin-angiotensin pathway modified this injury.
What was found
The abstract reports directional findings without numerical values or effect sizes. SARS-CoV infection and SARS-CoV Spike protein reduced ACE2 expression. Administration of SARS-CoV Spike protein worsened acute lung failure in mice, and this exacerbation was attenuated by inhibiting the renin-angiotensin pathway.
Why it matters
The study provides in vivo mechanistic evidence that SARS-CoV-mediated ACE2 downregulation drives acute lung failure, suggesting that renin-angiotensin system blockade could serve as a therapeutic strategy.
Limits
All findings are derived from animal models, with no human clinical validation presented. The abstract does not disclose sample sizes, specific control groups, dosing regimens, or quantitative outcome measures.
Cited by
- supports SARS-CoV-1 binds to ACE2, internalizes the receptor, downregulates ACE2 expression, and worsens acute lung injury.